DIRS.INFO The most relevant business & tech news

☆ 8 more of our stocks report earnings next week. Here's what we want to see
▼ + stars: | 2024-02-03 | by ( Zev Fima | ) www.cnbc.com time to read: +13 min

The three major averages posted gains for the fourth week in row, lifted by strong quarterly earnings results for most of the Big Tech companies and a strong jobs report. A weaker ADP Employment report on Wednesday provided no read-through to the monster January jobs report Friday. Here's what we're keeping an eye on in the coming week: 1. Earnings: It's another big earnings week head for the portfolio, with 8 more of our companies reporting. Consistency is what we appreciate most from nat gas giant Linde , so we're hoping for another quarter of solid earnings growth Tuesday.

Persons: Estee Lauder, Eli Lilly, Mounjaro, Nelson Peltz, Estée Lauder, Tyson, CARR, Jacobs, Willis Towers Watson, Edwards, Walt Disney, Oscar Health, Philip Morris, Armour, BAX, BILL, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: Big Tech, Dow Jones Industrial, Nasdaq, PMI, Apple, Starbucks, Procter, Gamble, GE Healthcare, DuPont, Linde, Ford, General Motors, Trian Partners, Disney, ESPN, Wynn Resorts, Wynn, Vegas, Prix, Estée Lauder Companies, Caterpillar, McDonalds Corp, Allegiant Travel, Bowlero Corp, Tyson Foods, TSN, Air Products & Chemicals, IDEXX Laboratories, CNA Financial Corp, CNA, Timken Company, Graham Corporation, Mesa Laboratories, Sphere Entertainment, Loews Corp, Technologies, Vertex Pharmaceuticals, Semiconductors, Simon Property Group, Amkor Technology, FMC Corporation, FMC, BellRing Brands, Crown Holdings, ChampionX Corporation, Golub Capital BDC, Flexsteel Industries, Kilroy Realty Corp, Gladstone Capital Corp, Unibanco, S.A, Snack Foods Corp, Kimball Electronics, Skyline Corp, Cabot Corporation, Simpson Manufacturing Co, Varonis Systems, Co, GE HealthCare, Linde plc, LIN, Spotify Technology S.A, BP, Hertz Global Holdings, AeroSystems Holdings, Toyota Motor Corp, Cummins, CMI, Software Technologies, AGCO Corporation, Carrier Global Corporation, Lear Corp, CONSOL Energy, Centene Corporation, Gartner, Arcbest Corp, CTS Corporation, Energizer Holdings, Hamilton Lane Incorporated, KKR, Precision Drilling Corporation, Frontier Group Holdings, Waters Corp, Alfa Laval, Aramark Holdings Corp, FirstService Corporation, Garden Sports Corp, New Jersey Resources Corp, nVent Electric plc, PJT Partners, Resources, Sensata Technologies, Ford Motor Company, Enphase Energy, Grill, VF Corp, Edwards Lifesciences Corp, Gilead Sciences, Lumen Technologies, Cognizant Technology Solutions Corp, Weatherford International plc, Amcor plc, Arrowhead Pharmaceuticals, Advanced Energy Industries, Uber Technologies, CVS Health, Roblox Corporation, Ares Capital Corp, Bunge, XPO Logistics, Scotts Miracle, Gro Company, Berry Global, Flex LNG, Equinor ASA, Griffon Corporation, OneMain Holdings, Brookfield Asset Management, Emerson Electric Co, Hilton Worldwide Holdings, Reynolds Consumer Products, Silicon Laboratories, Brands, Sciences, CDW Corp, Fox Corporation, WYNN, PayPal, Arm Holdings plc, ARM, Axcelis Technologies, Mattel, Paycom, Annaly Capital Management, McKesson Corp, Health Corporation, O'Reilly Automotive, Allstate Corp, Fluence Energy, Power Systems, Digital Turbine, Blue Bird Corp, Everest Group, Omega HealthCare, Coty, COTY, ConocoPhillips, Cameco Corp, Philip Morris International, Spirit Airlines, Hershey Company, Lightspeed Commerce, Aurora Cannabis, Lincoln National Corp, P, Tenet Healthcare Corp, Asbury Automotive Group, Arrow Electronics, Baxter International, PetMed, Boyd Gaming Corp, FirstEnergy Corp, Motorola Solutions, Terex Corp, PepsiCo, Growth, AMC Networks, Owl, American Pipeline, TELUS International, Magna International, Newell Brands, Jim Cramer's Charitable, CNBC, Bloomberg, Getty Locations: U.S, China, Macau, Wynn Macau, Valvoline, VVV, ALFVY, Madison, New Jersey, Gilead, Ceridian, ORLY, Paycor, Aurora, Provo , Utah

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Amazon, GM, Uber, Carvana, Nike, Palo Alto & more
▼ + stars: | 2023-12-04 | by ( Michael Bloom | ) www.cnbc.com time to read: +10 min

Wells Fargo downgrades Lululemon to equal weight from overweight Wells said in its downgrade of the stock that it sees less balanced risk/reward. Morgan Stanley downgrades Sea Limited to equal weight from overweight Morgan Stanley downgraded the Singapore-based tech conglomerate until its business outlook is clearer. Morgan Stanley upgrades Insulet to overweight from equal weight Morgan Stanley initiated the insulin pump therapy company and said it sees room for further gains. Wells Fargo reiterates Nike as overweight Wells says Nike is a top defensive pick for 2024. Morgan Stanley reiterates Palo Alto as overweight Morgan Stanley said Palo Alto shares have the poten tial to rise further.

Persons: Morgan Stanley, Mizuho, Wells, LULU, Roth, Evercore, Piper Sandler, Piper, NVDA, Goldman Sachs, Goldman, it's bullish, KeyBanc, Worthington Enterprises –, TD Cowen, Coinbase, underperform TD Cowen, Oppenheimer, Uber, Truist, Herc, Palo Organizations: West Bancorp, Bank of America, Union Pacific, US Bancorp, Motors, Mizuho, GM, UAW, UBS, Apple, Deutsche Bank downgrades Anheuser Busch InBev, Deutsche, Deutsche Bank, Airlines, Alaska, " Bank of America, Google, Walmart, Nvidia, AMD, European Partners, Coke, JPMorgan, of America, Magellan, MMP, Arrowhead Pharmaceuticals, Arrowhead Pharma, Worthington Steel, Worthington Industries, Worthington Enterprises, Barclays, Resources, Herc Holdings, United Rentals, Nike, Palo Alto, Palo Locations: China, Singapore, Indonesia

☆ Stocks making the biggest moves after hours: Salesforce, Pure Storage, Snowflake and more
▼ + stars: | 2023-11-29 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Salesforce — The software giant added 7% after releasing third-quarter adjusted earnings of $2.11 per share, higher than the $2.06 per share analysts polled by LSEG were expecting. The firm's third-quarter revenue of $8.72 billion fell in line with expectations. Snowflake — The stock rallied more than 7% after its third-quarter earnings beat analysts' expectations. Pure Storage — The data storage company lost 12%. Pure Storage anticipates fourth-quarter revenue will come in at $728 million, below the $918.7 million analysts had expected, according to FactSet.

Persons: LSEG, Nutanix, PVH Organizations: Arrowhead Pharmaceuticals

☆ Cramer's Lightning Round: Stay away from VinFast
▼ + stars: | 2023-09-07 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Norfolk Southern's year-to-date stock performance. Stock Chart Icon Stock chart icon Sofi's year-to-date stock performance. :Stock Chart Icon Stock chart icon VinFast's year-to-date stock performance. Stock Chart Icon Stock chart icon PG&E's year-to-date stock performance. Stock Chart Icon Stock chart icon Accenture's year-to-date stock performance.

Persons: I'm, Julie Sweet Organizations: Norfolk, Stock, Arrowhead Pharmaceuticals, Accenture, Alnylam Pharmaceuticals

☆ Small caps are finally starting to join the rally in June. Here's how to play their comeback
▼ + stars: | 2023-06-08 | by ( Fred Imbert | ) www.cnbc.com time to read: +3 min

Small stocks are making big moves this month, which could signal good news is ahead for Wall Street. The Russell 2000 , which is made up of small-cap names, is higher by 7% in June. .RUT 1M mountain Russell 2000 in past month "Moreover, small-caps have traditionally served as a bellwether in terms of the broader economic landscape," Krosby added. On top of that, Wolfe Research strategist Rob Ginsberg warned that the Russell 2000 could run into some technical resistance after the recent rally. That said, there are ways investors can try to capitalize on the small-cap rally.

Persons: Russell, Quincy Krosby, Krosby, Wolfe, Rob Ginsberg, Ginsberg Organizations: Financial, of Labor Statistics, Wolfe Research, CNBC Pro, Energy, NOVA, Beam Therapeutics, Rocket Pharmaceuticals, Arrowhead Pharmaceuticals Locations: U.S

☆ These stocks crushed it this week, including one name analysts expect to rally 95% from here
▼ + stars: | 2023-04-14 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Some individual stocks ran laps around the broader stock market this week. More than three-fourths of analysts covering the stock rate the stock a buy, with the average price target pointing to upside of 95.3% over the next year. Of these three stocks, only Bio-Techne is expected by the average analyst to see share prices rise in the next year. Outside of health, solar stocks Enphase and SunPower were also among the best performers this week. ENPH SPWR 5Y mountain Enphase and SunPower over the last 5 years — CNBC's Fred Imbert and Michael Bloom contributed to this report

☆ Biotech stocks that could surge more than 35% include one name targeting treatments for schizophrenia
▼ + stars: | 2023-02-09 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

Still, the outlook for biotech stocks could improve now , with innovation in new drugs and more merger and acquisition activity driving investor interest. Recently, Wall Street has been zoning in on developments in treatments for Alzheimer's diseases, drugs for weight loss and treatments using gene editing. CNBC Pro screened for biotech stocks that are part of the iShares Biotechnology ETF , searching for names with huge upside from current prices. In January, Piper Sandler initiated research coverage of Karuna with an overweight rating, saying it's "blazing a new trail in Schizophrenia" treatments. The stock was named another top 2023 pick by Piper Sandler, which said Legend has a "best-in-class" treatment for adults with relapsed multiple myeloma, a segment "with demand far outpacing supply."

☆ This little-known biotech stock can surge 60% on promising drug trials, Goldman Sachs says
▼ + stars: | 2022-11-15 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

It may be time for investors to jump into little-known biotech stock Fulcrum Therapeutics , according to Goldman Sachs. "We believe p38α/β MAPK inhibitor losmapimod has the potential to be a novel first-in-class therapy in FSHD," Kumar said in a note to clients. He has assumed a 40% probability of success and 40% peak market share for the FSHD drug. About 5% of the world's population carries the trait for hemoglobin disorders like sickle cell disease, according to the World Health Organization . Kumar said its FTX-6058 experimental drug for sickle cell disease, which is called SCD in short, has been promising in early testing.

Search resuls for: "Arrowhead Pharmaceuticals"

8 mentions found